|
|
|
 |
Exiqon A/S - Exiqon Announces 2012 Grant Program for MicroRNA Research |
|
|
Exiqon A/S (NASDAQ OMX Copenhagen: “EXQ”), a leading supplier of high-value
products for gene expression analysis, today announced the launch of its 2012
global research grant program, open to researc ... |
|
|
|
|
|
Exiqon A/S - Exiqon A/S’ share capital and total number of voting rights |
|
|
Pursuant to Section 6 of executive order no. 220 of 10 March 2010 about
issuers' disclosure obligations, it is hereby announced that Exiqon A/S' entire
share capital on 30 December 2011 is DKK 35,069, ... |
|
|
|
|
|
Exiqon A/S - Exiqon A/S increases its share capital in connection with exercise of warrants |
|
|
Exiqon A/S has today 8 December 2011 completed an increase of its share capital
by DKK 67,000, nominal value, as a result of an exercise of warrants. The
increase of the share capital is expected to b ... |
|
|
|
|
|
Exiqon A/S - Exiqon A/S Report regarding the management's and closely related parties' transactions with securities in Exiqon A/S |
|
|
Pursuant to section 28a of the Danish Securities Trading Act, Exiqon A/S
(NASDAQ OMX Copenhagen: “EXQ”) hereby announces the management's and their
closely related parties' transactions with shares an ... |
|
|
|
|
|
Exiqon A/S - INTERIM REPORT FOR THE PERIOD 1 JANUARY - 30 SEPTEMBER 2011 (UNAUDITED) |
|
|
Reported figures are for the full reporting period unless otherwise stated.
Figures for the comparable reporting period last year is stated in parenthesis
after realized figures. Comparative numbers i ... |
|
|
|
|
|
Exiqon A/S - Exiqon A/S announces financial calendar for 2012 |
|
|
Below are the expected dates for Exiqon A/S' annual general meeting and
financial reporting in 2012.
Financial calendar
Deadline for shareholders' proposal to the annual general 14 February 2 ... |
|
|
|
|
|
Exiqon A/S - Exiqon validates blood plasma-based miRNA PCR test for early detection of colorectal cancer |
|
|
Exiqon A/S (NASDAQ OMX Copenhagen: “EXQ”) today announced the presentation of
data at the 2011 EORTC-NCI-ASCO meeting in Brussels providing initial
validation of the company's blood plasma-based miRNA ... |
|
|
|
|
|
Exiqon A/S - Exiqon introduces new products for functional analysis of microRNA families |
|
|
Exiqon A/S (NASDAQ OMX: EXQ), a leading supplier of high-value products for
gene expression analysis, today announced the launch of its miRCURY LNA™
microRNA Family Inhibitors for efficient inactivati ... |
|
|
|
|
|
Exiqon A/S - Exiqon launches new products for the research and development of LNA™ based drugs |
|
|
Exiqon A/S (NASDAQ OMX: EXQ), a leading supplier of high-value products for
gene expression analysis, today announced the expansion of its product offering
to include LNA™ products for the research an ... |
|
|
|
|
|
Exiqon A/S - Exiqon A/S completes litigation against Santaris Pharma a/s |
|
|
Exiqon A/S (NASDAQ OMX Copenhagen: “EXQ”) today announced that the company has
completed its litigation against Santaris Pharma a/s.
In 2010, Exiqon initiated arbitration proceedings to defend its b ... |
|